Hamaguchi, Y., Kuwana, M., Hoshino, K.,Hasegawa, M., Kaji, K., Matsushita, T., Komura, K., Nakamura, M., Kodera, M., Suga, N., Higashi, A., Ogusu, K., Tsutsui, K., Furusaki, A., Tanabe, H., Sasaoka, S., Muro, Y., Yoshikawa, M., Ishiguro, N., Ayano, M., Muroi, E., Fujikawa, K., Umeda, Y., Kawase, M., Mabuchi, E., Asano, Y., Sodemoto, K., Seishima, M., Yamada, H., Sato, S., Takehara, K. and Fujimoto, M. (2011) Clinical Correlations with Dermatomyositis-Specific Autoantibodies in adult Japanese Patients with Dermatomyositis: A Multicenter Cross-Sectional Study. Archives of Dermatology, 147, 391-398. http://dx.doi.org/10.1001/archdermatol.2011.52

has been cited by the following article:

• TITLE: Clinical Phenotype of Japanese Patients with Dermatomyositis—Classification Based on Dermatomyositis-Specific Autoantibodies

  AUTHORS: Shinji Sato, Masataka Kuwana, Michito Hirakata, Shinichi Nogi, Noriko Sasaki, Naofumi Chinen, Kiri Honda, Eiko Saito, Takayuki Wakabayashi, Chiho Yamada, Yasuo Suzuki

  KEYWORDS: Dermatomyositis (DM), Interstitial lung Disease (ILD), Rapidly Progressive Interstitial Lung Disease (RP-ILD), Malignancy, Myositis-Specific Autoantibodies

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.4 No.2, June 4, 2014

  ABSTRACT: Objectives: To correlate the precise specificity of autoantibodies in Japanese dermatomyositis (DM) patients with their clinical phenotypes. Methods: Serum samples from 94 adult DM patients (67 with classical DM and 27 with clinically amyopathic dermatomyositis, CADM) were screened for autoantibodies using immunoprecipitation assays. Patients with antibodies against aminoacyl transfer RNA synthetase (ARS), Mi-2 or who had other autoantibodies were assessed for clinical symptoms and laboratory findings. Results: Sera from 27 of 94 DM patients (29%) were found to have anti-ARS antibodies. Nineteen (20%) had anti-CADM-140/MDA5, 5 (5%) had anti-Mi-2, and 8 (6%) had anti-p155/TIF1-γ. Anti-MJ/NXP-2 was not found in our series of adult DM. Seventeen patients with anti-ARS had fever and 22 had arthritis and interstitial lung disease (ILD), compatible with a diagnosis of anti-ARS syndrome. Seventeen of 19 (89%) with anti-CADM-140/MDA5 had ILD, 16 (84%) of whom developed rapidly progressive ILD (RP-ILD). Four of 5 (80%) with anti-Mi-2 had heliotrope rash and/or Gottron’s sign/papules, and 2 (40%) had V-sign and/or shawl-sign rash, whereas no ILD or malignancy was detected. As seen with anti-Mi-2-positive patients, a low frequency of ILD (13%) was found in patients with anti-p155/TIF1-γ but 6 of 8 (75%) had malignancy during their course. The frequency of ILD was significantly higher in patients with anti-ARS or anti-CADM-140/MDA5 compared with anti-Mi-2 or anti-p155/TIF1-γ (81% and 89%, respectively). It should be noted that anti-CADM-140/MDA5-positive patients suffered significantly more RP-ILD compared to patients with anti-ARS (84% vs. 7%, P